TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Why Amgen Stock Was a Nearly 5% Winner Today

The Motley Fool Logo The Motley Fool By Eric Volkman
Why Amgen Stock Was a Nearly 5% Winner Today

Amgen's stock rose nearly 5% following a strong Q3 earnings report, with Deutsche Bank raising its price target to $285 per share. The company demonstrated impressive revenue growth and positive performance across its top medicines.

Insights
JSPRW   negative

Company disclosed manufacturing issues in clinical trials, halted multiple studies, implemented cost-cutting measures, and experienced a 55.1% stock price drop, indicating significant operational and financial challenges


AMGN   positive

Reported double-digit revenue increase, beat analyst consensus projections, raised full-year guidance, and saw stock price rise on strong quarterly performance